Randomized trial assesses progression independent of relapse in MS cohorts, indicating MRI applications for treatment evaluation.
To determine whether progression independent of relapse (PIRA) and conventional MRI (cMRI) activities in multiple sclerosis (MS) can be detected in active relapsing-remitting MS (RRMS) cohorts across clinical trials of approved disease-modifying therapies (DMTs).
No takes yet. Share an insight, caveat, or question.
Hentati et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: